secwatch / observer
8-K filed June 4, 2026, 8:00 AM ET ticker IMNN CIK 0000749647
debt confidence high sentiment neutral materiality 0.70

Imunon, Inc. (IMNN): debt financing — IMUNON secures up to $10M through preferred stock and secured notes for Phase 3 trial

Imunon, Inc.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Imunon, Inc. incurred debt of $5,000,000 with Streeterville Capital, LLC at 5% per annum maturing 18 months following the Closing Date.

Principal
$5,000,000
Counterparty
Streeterville Capital, LLC
Rate
5% per annum
Maturity
18 months following the Closing Date
Event
incurrence
Exact text from the filing
(ii) a Secured Promissory Note A-1 in an original principal amount of $2,720,000 (the “ A-1 Note ”); and (iii) a Secured Promissory Note B in an original principal amount of $5,000,000 (the “ B Note ” and together with the A-1 Note, the “ Notes ”). The transactions contemplated by the Securities Purchase Agreement (collectively, the “ Transaction ”) closed on
View on SEC.gov
Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Imunon, Inc. incurred debt of $2,720,000 with Streeterville Capital, LLC at 8% per annum maturing 18 months following the Closing Date.

Principal
$2,720,000
Counterparty
Streeterville Capital, LLC
Rate
8% per annum
Maturity
18 months following the Closing Date
Event
incurrence
Exact text from the filing
(the “ Series A Preferred Stock ”), at a price of $10,000 per share, for aggregate proceeds of $2,500,000; (ii) a Secured Promissory Note A-1 in an original principal amount of $2,720,000 (the “ A-1 Note ”); and (iii) a Secured Promissory Note B in an original principal amount of $5,000,000 (the “ B Note ” and together with the A-1 Note, the “ Notes ”). The
View on SEC.gov
Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Imunon, Inc.: Filed a Certificate of Designation for Series A Preferred Stock designating 400 shares (effective 2026-06-01).

Change
charter amendment
Effective
2026-06-01
Exact text from the filing
On June 1, 2026, the Company filed a certificate of designation of preferences and rights (the “ Certificate of Designation ”) of the Series A Preferred Stock with the Secretary of State of the State of Delaware, designating 400 shares of Series A Preferred Stock, which became effective upon filing.
View on SEC.gov
Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.99

Imunon, Inc. entered into Securities Purchase Agreement with Streeterville Capital, LLC valued at Total financing of $10,000,000; issuance of 250 shares of Series A Preferred Stock at $10,000 per sh (effective 2026-06-02).

Action
entry
Agreement
equity purchase
Counterparty
Streeterville Capital, LLC
Value
Total financing of $10,000,000; issuance of 250 shares of Series A Preferred Stock at $10,000 per sh
Effective
2026-06-02
Exact text from the filing
On June 2, 2026, Imunon, Inc. (the “ Company ”) entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with Streeterville Capital, LLC (the “ Investor ”), providing for the issuance and sale by the Company, and the purchase by the Investor, of (i) 250 shares (the “ Preferred Shares ”) of the Company’s Series A Preferred Stock, par value $0.01 per share (the “ Series A Preferred Stock ”), at a price of $10,000 per share, for aggregate proceeds of $2,500,000; (ii) a Secured Promissory Note A-1 in an original principal amount of $2,720,000 (the “ A-1 Note ”); and (iii) a Secured Promissory Note B in an original principal amount of $5,000,000 (the “ B Note ” and together with the A-1 Note, the “ Notes ”).
View on SEC.gov

296 debt financings filed in the last 30 days. Browse all debt financings →

Imunon, Inc. filing history →

Source: SEC EDGAR
accession 0001493152-26-027201
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.